Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS026 and JS016 in healthy Chinese subjects
NCT05167279Phase 1Completed
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Dec 2021
- Primary completion
- Dec 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of JS026 in coronavirus disease 2019 (COVID-19), sponsored by Shanghai Junshi Biosciences Co., Ltd. Started Dec 2021; status: completed.
02
Drugs
JS026
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05167279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05167279.